Nuvalent
a rationally designed alk selective sparing inhibitor needs preliminary phase conclusions else alk gen gen gen investigational gen activity alk single mutant activity alk compound mutant activity activity alk activity activity observed in patients with alk including after exhausting available therapies alk single mutant activity activity observed in patients with diverse single alk resistance mutations alk compound mutant activity activity observed in patients with diverse compound alk resistance mutations activity avoiding activity observed in patients with history of including intracranial responses i i i emerging safety profile was consistent with design i key observed in clinical investigation source lin head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
14 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
February 2024
a rationally designed alk selective sparing inhibitor medical needs preliminary phase conclusions alk gen gen gen investigational gen activity alk single mutant activity alk compound mutant activity activity avoiding alk activity activity observed in patients with alk including after exhausting available therapies alk single mutant activity activity observed in patients with diverse single alk resistance mutations alk compound mutant activity activity observed in patients with diverse compound alk resistance mutations activity avoiding activity observed in patients with history of including intracranial responses emerging safety profile was consistent with design key observed in clinical investigation source lin head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Investor Presentation
January 2024
a rationally designed alk selective sparing inhibitor medical needs alk gen gen gen lin preliminary phase conclusions investigational gen alk activity alk single mutant activity alk compound mutant activity ens activity avoiding alk activity observed in patients with alk including after exhausting available therapies alk single mutant activity activity observed in patients with diverse single alk resistance mutations alk compound mutant activity activity observed in patients with diverse compound alk resistance mutations activity air avoiding activity observed in patients with history of including intracranial responses emerging safety profile was consistent with design key observed in clinical investigation source lin head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Investor Presentation
January 2024
a rationally designed alk selective sparing inhibitor medical needs alk gen gen gen lin preliminary phase conclusions investigational gen alk activity alk single mutant activity alk compound mutant activity ens activity avoiding alk activity observed in patients with alk including after exhausting available therapies alk single mutant activity activity observed in patients with diverse single alk resistance mutations alk compound mutant activity activity observed in patients with diverse compound alk resistance mutations activity air avoiding activity observed in patients with history of including intracranial responses emerging safety profile was consistent with design key observed in clinical investigation source lin head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Related slides by other companies
Kymera
Investor Presentation
December 2023
response and stable disease observed across multiple tumor types during dose of | Kymera
Compass Therapeutics
Investor Presentation
May 2023
potential best in class agonist | Compass Therapeutics
Compass Therapeutics
Investor Presentation
May 2022
potential best in class agonist | Compass Therapeutics
Erasca
IPO
July 2021
examples of single agent clinical activity of eras responses in melanoma and salivary gland adenocarcinoma pease | Erasca
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io